Institutional equity research forecasts establish a twelve-month consensus price target of approximately ₹885 for Alembic Pharmaceuticals stock. This base-case projection implies a healthy percentage upside from its prevailing trading range, supported by anticipated earnings recovery, sector re-rating potential, and operational efficiencies. More optimistic bull-case scenarios stretch toward ₹1,050 assuming robust margin expansion, while conservative bear-case parameters project lower bounds near ₹590 if competitive pressures or regulatory headwinds persist. Investors should view these targets as analytical projections rather than guaranteed financial outcomes.